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INTRODUCTION
Mycoplasma pneumoniae (Mp) is the second most common 
cause of community-acquired pneumonia (CAP) in Korea,
1 but 
is the most common pathogen in school-age children and ado-
lescents (≥40% of CAP in this age group).
2 It also affects children 
below five years of age and typically causes Mp pneumonia, that 
is usually benign and self-limited. However, Mp infection is ac-
companied by extrapulmonary manifestations in about 20-25% 
of infected children.
3 Infection may present with a multitude of 
symptoms and signs, such as hepatic, hematological, musculo-
skeletal, cardiac, dermatological, gastrointestinal, neurological, 
and renal symptoms before, during, after or even in the absence 
of respiratory symptoms. Life-threatening conditions occur very 
rarely in previously healthy children. Here, we report a case of 
multiple organ failure with an unfavorable outcome associated 
with Mp infection, despite intensive treatment. 
CASE REPORT
A 12-year-old boy who looked severely ill was transferred to 
our hospital due to a fever lasting for three days and intolerable 
epigastric pain. He had been diagnosed with unspecified pneu-
monia without any distinctive respiratory symptoms and treat-
ed with cefotaxime and amikacin for 14 days. On physical ex-
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amination, scattered petechiae and purpura were observed on 
various regions of his body. Additionally, there was hepatomeg-
aly and severe tenderness in the right upper quadrant.
Initial laboratory findings revealed leukocytosis (21,100/mm
3, 
range 4,000-10,000) and thrombocytopenia (98,000/mm
3, range 
150,000-450,000). The C-reactive protein level was high at 17.50 
mg/dL (range 0.0-0.8). Elevated serum creatinine (Cr, 1.7 mg/
dL), oliguria (240 mL) for more than 24 hours, and urine spot 
analysis with low sodium excretion fraction (0.62) revealed acute 
kidney injury. There was also acute hepatic failure, as indicated 
by markedly high aspartate aminotransferase (AST, 2,023 U/L; 
range 5-40), alanine aminotransferase (ALT, 482 U/L; range 
8-40), and γ-glutamyl transferase (106 IU/L; range 10-75 IU/L). 
Prothrombin time (PT) was 24.9 seconds (INR 2.12) and acti-
vated partial thromboplastin time (aPTT) 123 seconds. Serum 
creatinine kinase (CK) was 5,248 mg/dL (range 30-180), lactate 
dehydrogenase 8,740 U/L (range 100-200), serum myoglobin 
273.6 ng/mL (range 0.0-72.0), and urine myoglobin 2,927 ng/
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Mycoplasma pneumoniae (Mp) is a unique pathogen that causes not only pulmonary but also extrapulmonary manifestations that must be rapidly 
diagnosed. A 12-year-old boy, with no relevant medical history, presented with fever, severe epigastric pain, and vomiting. Laboratory findings 
showed fulminant and cholestatic hepatitis, hemolytic anemia, thrombocytopenia, acute kidney injury, disseminated intravascular coagulopathy, 
acute myocardial infarction, and rhabdomyolysis. His clinical condition rapidly deteriorated during intubation and continuous renal replacement ther-
apy. Despite intensive treatment, he did not recover. We report a case of fulminant and fatal multiple organ failure in a previously healthy boy with 
Mp infection, describing the possible pathomechanisms of multiple organ failure involved in the disease.
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mL (range 0.0-30), suggesting severe rhabdomyolysis. 
Twelve hours after admission, serial laboratory testing indi-
cated rapidly deteriorating multiple organ failure (Table). Liver 
function results were serum AST, 33,221 U/L; ALT, 11,096 U/L; 
total bilirubin, 9.9 mg/dL (range 0.2-1.2); direct bilirubin, 4.0 
mg/dL (range 0.0-0.4); and ammonia (NH3) 117 μmol/L (range 
0.0-54). PT and aPTT were markedly prolonged over 200 sec-
onds. Serum Cr and uric acid concentrations had also increased 
to 2.9 mg/dL and 10.3 mg/dL, respectively. Serum electrolyte 
levels showed hyponatremia (Na
+ 129 mMol/L), hyperkalemia 
(K
+ 7.1 mMol/L) and severe metabolic acidosis (tCO2 8 mMol/
L). D-dimer, fibrinogen degradation product and antithrombin 
III were 37,492 ng/mL (range 0.0-200), above 20 ng/mL (range 
0.0-4.0), and 48% (range 65-125), respectively. The patient was 
stuporous, and we decided to intubate and to apply continuous 
renal replacement therapy (CRRT) using veno-venous hemodi-
afiltration to remove all toxins such as myoglobin and proin-
flammatory cytokines, and to restore the functions of failed or-
gans.
On hospital day 3, pleural effusion was found on a chest ra-
diogram, and thoracostomy was performed (Figure). Viral 
markers for hepatitis, blood cultures, sputum cultures, and au-
toantibodies were all negative. However, over two weeks, the ti-
ter of anti-mycoplasma IgM and IgG antibodies increased from 
below 1:40 to more than 1:1,280 IU/mL. Intravenous clarithro-
mycin had been administered from admission day due to sus-
picion of Mp. An electroencephalogram showed the severe iso-
electric pattern of diffuse encephalopathy, suggesting a critical 
prognosis. The electrocardiography recorded ventricular tachy-
cardia and precordial ST segment elevation, both signs of acute 
myocardiac infarction, with elevated CK-MB enzymes of 278.2 
μg/L (range 0.0-5.0). The patient went into cardiac arrest and 
did not recover.
DISCUSSION
Over the last 20 years, unusual and extrapulmonary manifes-
tations of the Mp infection have been reported only infrequent-
ly.
3,4 Most reported cases showed favorable outcomes, and ful-
minant and fatal multiple organ involvement, with more than 
nine extrapulmonary manifestations simultaneously (fulminant 
and cholestatic hepatitis, hemolytic anemia, thrombocytopenic 
purpura, rhabdomyolysis, pleural effusion, acute kidney injury, 
disseminated intravascular coagulopathy, myocarditis, and 
Table.  Laboratory findings during hospitalization
Findings Admission 8 hr 16 hr 24 hr 48 hr 72 hr
White blood cell (/mm
3) 21,100 25,400 35,200 26,600 12,100 9,700
Hemoglobin (g/dL) 14.0 14.3 15.1 8.0 7.2 10.6
Platelet (10
3/µ) 98 60 66 90 88 86
Blood urea nitrogen (mg/dL) 18.5 24.5 20.5 20.3 7.3 4.8
Creatinine (mg/dL) 1.7 2.7 2.7 2.9 1.7 2.0
Albumin (g/dL) 3.6 3.5 3.1 2.3 3.4 3.5
Total bilirubin (mg/dL) 4.0 2.7 2.3 4.6 9.9
Direct bilirubin (mg/dL) 0.9 1.2 1.5 2.1 4.0
Aspartate aminotransferase (U/L) 2,023 3,291 7,681 12,143 33,321 15,100
Alanine aminotransferase (U/L) 482 1,563 4,039 4,983 11,096 4,703
C-reactive protein (mg/dL) 17.59 15.79 7.7 5.69
Creatine kinase (IU/L) 5,248 12,047 17,326 28,310
Creatine kinase-MB (ng/dL) 15.0 278.2
Lactate dehydrogenase (IU/L) 8,740 28,802 22,751 18,567
Prothrombin time (sec) 24.9 28.0 31.1 150.0 46.8 35.7
Activated partial thromboplastin time (sec) 123 127 200 200 113 62
Fibrinogen (mg/dL) 173 60 120
Mycoplasma antibody titer ≤1:40* ≥1:1,280
*Performed at a local clinic.
Figure. Chest radiograms showing (A) initial status on admission (B) pleural ef-
fusion followed by thoracostomy.
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acute myocardial infarction), as seen in our patient, was ex-
tremely rare.
The exact pathomechanism of the Mp infection-induced mul-
tiple organ failure remains unclear. It has been postulated that 
the cytadherence of Mp, cell invasion, cytotoxicity, immune re-
sponse, and cytokine production might be involved in its 
pathogenicity.
5,6 Recently, Narita
7 suggested a plausible patho-
genesis of the extrapulmonary manifestations of Mp infection, 
classifying them into three categories: Firstly, a direct-type, as-
sociated with inflammatory cytokines induced locally by lipo-
proteins contained in the bacterial cell membrane. Secondly, 
an indirect-type, associated with immune modulation, such as 
autoimmunity, allergy, or immune complexes. Thirdly, a vascu-
lar occlusion-type, associated with vasculitis and/or thrombo-
sis, with or without a systemic hypercoagulable state induced 
by the bacterium. The production of various pro-inflammatory 
cytokines, such as tumor necrosis factor-α, interferon-γ, and in-
terleukin-8, may occur in all three types. Gehrs et al.
8 reported 
that hemolytic anemia in Mp infection was mediated by the 
Mp-associated cold antibody (IgM), and that cold agglutinins 
developed during the second and third week of illness. The tox-
icity of Mp infection is prominent in the late stages of the ill-
ness.
9 
In the majority of children, Mp–associated hepatitis is usually 
self-limited, but fulminant hepatitis with unfavorable outcome 
can develop, as seen in the case presented here. Berg et al.
10 
found that Mycoplasma antigens can trigger the induction of 
anti-mitochondrial antibodies, especially through MpPDC-E2-
related antibodies and immune reactivity. Carrascosa et al.
11 
also reported a case of lethal hepatitis associated with hepato-
toxic drug treatment in a patient with acute Mp infection.
In this case, CRRT was started early, but was not successful. 
However, CRRT is recommended as the treatment of choice 
when rhabdomyolysis coexists with acute kidney injury. Serial 
serologic testing of Mp infection is necessary for early diagnosis 
and appropriate macrolide treatment, which is mandatory in 
order to rescue patients with extrapulmonary manifestations. 
Corticosteroids can also be used in combination with macro-
lide antibiotics, for supplementary anti-inflammatory effects.
12 
However, our patient did not recover, despite CRRT and corti-
costeroid treatment.
In conclusion, fulminant and fatal multiple organ failure might 
be associated with Mp infection in children through various 
pro-inflammatory cytokines. Even in cases with no respiratory 
symptoms, we emphasize the necessity of awareness of the va-
riety and severity of Mp infection in children presenting with 
extrapulmonary manifestations. Additionally, an accumulation 
of clinical reports is important for distinguishing what Mp can 
and cannot cause, on the basis of biological ability, because 
Mycoplasma infections are strictly species-specific.
7
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